Portulaca oleracea Extract Ameliorates Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Male Sprague-Dawley Rats.

Publisher: John Wiley & Sons Ltd Country of Publication: England NLM ID: 101678837 Publication Model: Print Cited Medium: Internet ISSN: 2053-1095 (Electronic) Linking ISSN: 20531095 NLM ISO Abbreviation: Vet Med Sci Subsets: MEDLINE

Original Publication: [Oxford] : John Wiley & Sons Ltd., [2015]-

Prostatic Hyperplasia*/chemically induced ; Prostatic Hyperplasia*/drug therapy ; Prostatic Hyperplasia*/veterinary ; Rats, Sprague-Dawley* ; Portulaca*/chemistry ; Testosterone Propionate* ; Plant Extracts*/pharmacology ; Plant Extracts*/administration & dosage; Animals ; Male ; Rats ; Finasteride/pharmacology

Benign prostatic hyperplasia (BPH) is a distressing health problem that can cause serious complications in aging men. Androgens are implicated in the causation of BPH. Portulaca oleracea (PO) is a natural product with diverse pharmacological effects. The objective of this study was to investigate the effect of PO in a rat model of testosterone propionate (TP)-induced BPH and explore the underlying mechanisms. Thirty-five Sprague-Dawley (SD) rats were divided into the following equal groups (n = 7): normal control (NC) group, TP (3 mg/kg) group, finasteride (10 mg/kg) group, 25 and 50 mg/kg PO groups. At the end of the experiment, the body weights (BWs) of the rats were measured before they were euthanized to the establishment obtain serum and prostate weight (PW). TP-induced levels of androgen-related proteins in the prostate were also investigated. In the TP group, prostate size, BW, serum DHT level, prostate epithelial cell thickness and androgen-related protein level were higher than those in the NC group (p < 0.001). PO reversed TP-induced BPH in a dose-dependent manner (p < 0.01) and its effect was similar to that of finasteride. A similar effect of PO on the androgen-related protein level was also observed. We successfully established a TP-induced BPH rat model. This is the first study to demonstrate that inhibition of androgen-related proteins using PO can alleviate BPH.
(© 2024 The Author(s). Veterinary Medicine and Science published by John Wiley & Sons Ltd.)

Antioxidants (Basel). 2022 Jun 11;11(6):. (PMID: 35740046)
Int J Environ Res Public Health. 2019 May 16;16(10):. (PMID: 31100850)
Curr Pharm Des. 2006;12(7):775-83. (PMID: 16515494)
Curr Urol Rep. 2019 Aug 3;20(9):54. (PMID: 31377881)
Prostate. 1993;22(1):39-42. (PMID: 7678931)
Nat Rev Urol. 2016 Sep 30;13(10):613-26. (PMID: 27686153)
Rev Endocr Metab Disord. 2022 Dec;23(6):1221-1231. (PMID: 35748976)
Curr Aging Sci. 2021;14(2):124-132. (PMID: 33535964)
Horm Mol Biol Clin Investig. 2017 Feb 1;29(2):71-77. (PMID: 27802175)
Asian J Urol. 2020 Jul;7(3):191-202. (PMID: 32742923)
Cancer Res. 2011 Feb 15;71(4):1486-96. (PMID: 21303972)
Redox Rep. 2021 Dec;26(1):1-9. (PMID: 33416009)
Molecules. 2021 Nov 25;26(23):. (PMID: 34885733)
Molecules. 2023 Aug 03;28(15):. (PMID: 37570829)
Differentiation. 2011 Nov-Dec;82(4-5):184-99. (PMID: 21620560)
Cochrane Database Syst Rev. 2019 Feb 13;2:CD013143. (PMID: 30759311)
Am J Mens Health. 2015 May;9(3):222-8. (PMID: 24928450)
J Adv Res. 2024 Mar;57:135-147. (PMID: 37061215)
Mol Biol Rep. 2012 Aug;39(8):7981-8. (PMID: 22576880)
J Ethnopharmacol. 2004 Jul;93(1):57-62. (PMID: 15182905)
J Cutan Aesthet Surg. 2009 Jan;2(1):12-6. (PMID: 20300365)
Clin Exp Hypertens. 2022 Oct 3;44(7):663-669. (PMID: 35972305)
Rev Urol. 2003;5 Suppl 5:S3-S11. (PMID: 16985968)
Biomed Pharmacother. 2023 Apr;160:114389. (PMID: 36791565)
Oncotarget. 2017 Feb 7;8(6):9500-9512. (PMID: 27880726)
Exp Gerontol. 2021 Jan;143:111152. (PMID: 33189835)
Cell Death Dis. 2022 Jun 17;13(6):554. (PMID: 35715415)
Nutrients. 2019 Sep 12;11(9):. (PMID: 31547405)
Med Clin North Am. 2018 Mar;102(2):301-311. (PMID: 29406059)
Mol Cell. 2016 Sep 15;63(6):976-89. (PMID: 27594448)
Innate Immun. 2021 Apr;27(3):230-239. (PMID: 33611955)
Appl Clin Genet. 2020 Apr 14;13:83-96. (PMID: 32346305)
Int J Androl. 2010 Jun 1;33(3):475-88. (PMID: 19508330)
J Am Osteopath Assoc. 2008 Jul;108(7):333-7. (PMID: 18648026)
Am J Transl Res. 2016 May 15;8(5):2138-48. (PMID: 27347321)
Aging Male. 2019 Mar;22(1):12-19. (PMID: 29392976)
Cancers (Basel). 2020 Mar 21;12(3):. (PMID: 32245249)
Hum Reprod Update. 2001 May-Jun;7(3):236-47. (PMID: 11392370)
Curr Drug Discov Technol. 2021;18(4):518-524. (PMID: 32532194)
Asia Pac J Clin Nutr. 2007;16 Suppl 1:227-33. (PMID: 17392109)
J Cell Biochem. 2019 Sep;120(9):14875-14884. (PMID: 31016763)
Evid Based Complement Alternat Med. 2019 Jul 31;2019:6369132. (PMID: 31467577)
Biomed Pharmacother. 2023 Nov;167:115566. (PMID: 37778273)
J Evid Based Complementary Altern Med. 2017 Oct;22(4):562-566. (PMID: 29228809)
Gerontology. 2019;65(5):458-464. (PMID: 30943489)
J Ethnopharmacol. 2009 Jul 15;124(2):246-50. (PMID: 19397978)
J Ethnopharmacol. 2017 Jun 9;205:158-172. (PMID: 28495602)
J Cell Physiol. 2019 Aug;234(10):17444-17458. (PMID: 30820960)
Toxicol Res. 2022 Dec 7;39(2):179-190. (PMID: 37008695)
Chin Herb Med. 2022 Aug 13;15(1):110-116. (PMID: 36875440)
Am J Pathol. 2013 Jun;182(6):1942-9. (PMID: 23570837)
Biomed Res Int. 2015;2015:925631. (PMID: 25692148)
Molecules. 2019 Aug 08;24(16):. (PMID: 31398934)
Int J Mol Sci. 2021 Aug 21;22(16):. (PMID: 34445725)
Ann Pharmacother. 2012 Sep;46(9):1245-9. (PMID: 22851743)
J Cell Sci. 2008 Aug 1;121(Pt 15):2578-87. (PMID: 18628304)
N Engl J Med. 2003 Jul 17;349(3):215-24. (PMID: 12824459)

Keywords: Portulaca oleracea; androgen‐related proteins; benign prostatic hyperplasia; testosterone propionate

WI93Z9138A (Testosterone Propionate)
0 (Plant Extracts)
57GNO57U7G (Finasteride)

Date Created: 20241231 Date Completed: 20241231 Latest Revision: 20250104

20250114

PMC11687364

10.1002/vms3.70184

39739367